吸入型吡非尼酮溶液(AP01)治疗特发性肺纤维化:一项随机、开放标签、剂量递增试验
100mg每日两次组24周和48周FVC%预计值保持稳定,常见不良反应较口服吡非尼酮更少。
要点
- AP01 100mg每日两次组24周和48周FVC%预计值变化分别为0.6和-0.4,保持稳定。
- 最常见治疗相关不良事件为咳嗽、皮疹、恶心,均为轻中度。
- 口服吡非尼酮常见副作用在AP01吸入给药中频率较低。
核心结论
- 吸入型吡非尼酮AP01 100mg每日两次组患者24周和48周FVC%预计值保持稳定。
- AP01常见治疗相关不良事件均为轻中度,且口服吡非尼酮常见副作用频率较低。
- 研究认为值得进一步研究AP01。
研究设计与样本
- 1b期、随机、开放标签、剂量递增试验,在6国25个中心开展。
- 随机1:1接受雾化AP01 50mg每日一次(n=46)或100mg每日两次(n=45),最长72周。
- 主要终点为第24周,同时报告第48周结果以与已发表抗纤维化试验比较。
主要发现
- 50mg每日一次组24周和48周FVC%预计值变化分别为-2.5(95%CI -5.3至0.4,-88mL)和-4.9(-7.5至-2.3,-188mL)。
- 100mg每日两次组24周和48周FVC%预计值变化分别为0.6(-2.2至3.4,10mL)和-0.4(-3.2至2.3,-34mL)。
- 最常见治疗相关不良事件为咳嗽(14例,15.4%)、皮疹(11例,12.1%)、恶心(8例,8.8%)、咽喉刺激(5例,5.5%)、疲劳(4例,4.4%),以及味觉障碍、头晕和呼吸困难各3例(3.3%)。
临床怎么用
- 对于口服抗纤维化药物不耐受、不愿或不符合条件的IPF患者,吸入型吡非尼酮100mg每日两次可能稳定肺功能。
- AP01常见不良反应为轻中度咳嗽、皮疹、恶心等,需关注并管理。
局限性
- 本研究为开放标签设计,非双盲。
- 第72周数据将与正在进行的开放标签扩展研究合并另行分析报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Systemic exposure can have significant side effects, including nausea, rash, photosensitivity, weight loss and fatigue. Reduced doses may be suboptimal in slowing disease progression. METHODS: This phase 1b, randomised, open-label, dose-response trial at 25 sites in six countries (Australian New Zealand Clinical Trials Registry (ANZCTR) registration number ACTRN12618001838202) assessed safety, tolerability and efficacy of inhaled pirfenidone (AP01) in IPF. Patients diagnosed within 5 years, with forced vital capacity (FVC) 40%-90% predicted, and intolerant, unwilling or ineligible for oral pirfenidone or nintedanib were randomly assigned 1:1 to nebulised AP01 50 mg once per day or 100 mg two times per day for up to 72 weeks. RESULTS: We present results for week 24, the primary endpoint and week 48 for comparability with published trials of antifibrotics. Week 72 data will be reported as a separate analysis pooled with the ongoing open-label extension study. Ninety-one patients (50 mg once per day: n=46, 100 mg two times per day: n=45) were enrolled from May 2019 to April 2020. The most common treatment-related adverse events (frequency, % of patients) were all mild or moderate and included cough (14, 15.4%), rash (11, 12.1%), nausea (8, 8.8%), throat irritation (5, 5.5%), fatigue (4, 4.4%) and taste disorder, dizziness and dyspnoea (three each, 3.3%). Changes in FVC % predicted over 24 and 48 weeks, respectively, were -2.5 (95% CI -5.3 to 0.4, -88 mL) and -4.9 (-7.5 to -2.3,-188 mL) in the 50 mg once per day and 0.6 (-2.2 to 3.4, 10 mL) and -0.4 (-3.2 to 2.3, -34 mL) in the 100 mg two times per day group. DISCUSSION: Side effects commonly associated with oral pirfenidone in other clinical trials were less frequent with AP01. Mean FVC % predicted remained stable in the 100 mg two times per day group. Further study of AP01 is warranted. TRIAL REGISTRATION NUMBER: ACTRN12618001838202 Australian New Zealand Clinical Trials Registry.
引用
- West A, Chaudhuri N, Barczyk A, et al. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023. PMID: 36948586. doi:10.1136/thorax-2022-219391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。